What is BioCryst Pharmaceuticals's raw materials?

BioCryst Pharmaceuticals (BCRX) reported raw materials of $8.33M in Q1 2026.

How has BioCryst Pharmaceuticals's raw materials changed year-over-year?

BioCryst Pharmaceuticals's raw materials decreased by 4.7% year-over-year, from $8.74M to $8.33M.

What is the long-term trend for BioCryst Pharmaceuticals's raw materials?

Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's raw materials has grown at a 3.9% compound annual growth rate (CAGR), from $8.91M to $10M.

BioCryst Pharmaceuticals BCRX Raw materials

Raw materials at other companies

ANI PharmaceuticalsANIP

——

BridgeBio PharmaBBIO

——

PrecigenPGEN

——

HRO

HarrowHROW

——

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterials.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's raw materials?: BioCryst Pharmaceuticals (BCRX) reported raw materials of $8.33M in Q1 2026.
How has BioCryst Pharmaceuticals's raw materials changed year-over-year?: BioCryst Pharmaceuticals's raw materials decreased by 4.7% year-over-year, from $8.74M to $8.33M.
What is the long-term trend for BioCryst Pharmaceuticals's raw materials?: Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's raw materials has grown at a 3.9% compound annual growth rate (CAGR), from $8.91M to $10M.